<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384291</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-BG-01</org_study_id>
    <nct_id>NCT02384291</nct_id>
  </id_info>
  <brief_title>Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone vs. Commercially Available Bone Graft</brief_title>
  <official_title>Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone Versus Commercially Available Bone Graft. A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha - Bio Tec Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha - Bio Tec Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to compare the regenerative outcome of using separately two
      different Xenografts during sinus floor augmentation.

      Aim of this prospective randomized-controlled clinical trial is to compare the regenerative
      results of Alpha-Bio's GRAFT Natural Bovine Bone versus commercially available bone graft
      after two-step sinus floor elevations by clinical and histological analysis.

      Clinical Parameters are wound healing parameters, radiological volume stability and implant
      survival rates. Histological parameters are based on a histomorphometrical analysis of
      trephine cores harvested in progress of implant bed preparation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological bone formation following sinus floor augmentation [ evaluated by biopsies harvested from the implant sites]</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone volume-stable results six months following augmentation procedures [ demonstrated by X-ray evaluation].</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Sinus Floor Augmentation</condition>
  <arm_group>
    <arm_group_label>Alpha-Bios GRAFT Natural Bovine Bone treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pure Hydroxyapatite ceramic mineral with high similarity to the human bone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>natural bone substitute</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>natural bone substitute material derived from the mineral portion of bovine bone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alpha-Bio GRAFT Natural Bovine Bone</intervention_name>
    <description>Pure Hydroxyapatite ceramic mineral with high similarity to the human bone</description>
    <arm_group_label>Alpha-Bios GRAFT Natural Bovine Bone treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>natural bone substitute</intervention_name>
    <description>natural bone substitute material derived from the mineral portion of bovine bone</description>
    <arm_group_label>natural bone substitute</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who will present with a moderately or severely atrophic posterior maxilla
             with 1-6 mm residual alveolar bone will be selected for the study.

          2. Men and women over the age of 18 years.

          3. Patient has signed the Informed Consent.

        Exclusion Criteria:

          1. Chronic steroid therapy,

          2. Uncontrolled diabetes,

          3. Cardiovascular disease,

          4. Past irradiation of head and neck

          5. Maxillary sinus cysts,

          6. Active chronic sinusitis,

          7. Smoking more than ten cigarettes per day during the 3 months preceding this study .

          8. Malignant disease in the 5 years preceding this study

          9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia,
             granulocytopenia

         10. Disease that compromise the immune system

         11. Psychiatric disorder

         12. Hypersensitivity to titanium, collagen or bovine bone.

         13. Women who are pregnant or nursing.

         14. Patients with non-treated periodontal disease.

         15. Medical and/or general contraindications for intraoral surgical procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Rothamel, Priv-Doz Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Craniomaxillofacial and Plastic Surgery University Hospital of Cologne</affiliation>
  </overall_official>
  <link>
    <url>http://www.alpha-bio.net/global</url>
    <description>Sponsor site</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

